Kilitch Drugs (India) Limited reported a consolidated net profit of ₹32.39.96 lakh for the fiscal year ended March 31, 2026 (FY26), an increase from ₹31.15.69 lakh in FY25, driven by robust export sales and improved operational efficiencies. The pharmaceutical manufacturer has scheduled its 34th Annual General Meeting (AGM) for August 27, 2026, to seek shareholder approval for performance-linked incentives totaling ₹2 crore for its executive directors and to ratify the remuneration of its cost auditors.

The Board of Directors approved these resolutions during a meeting held on July 28, 2026, in compliance with Regulation 30 and Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has closed its Register of Members and Share Transfer Books from August 20, 2026, to August 27, 2026, both days inclusive, to determine shareholders entitled to vote. This closure is mandated under Regulation 42 of the SEBI Listing Regulations.

Key Financial Performance

Kilitch Drugs achieved a consolidated revenue from operations of ₹23,547.49 lakh in FY26, compared to ₹19,831.85 lakh in the previous year. The growth was primarily fueled by export sales, which stood at ₹13,281.46 lakh, representing a significant portion of the total income. Standalone revenue from operations also rose to ₹18,857.43 lakh from ₹18,158.73 lakh.

The company’s EBITDA for the consolidated entity was ₹4,628.47 lakh. Management highlighted that the new greenfield manufacturing facility at Pen, Maharashtra, is now operational in phases, strengthening manufacturing capabilities and supply chain resilience.

Executive Compensation and AGM Agenda

The primary special business involves approving Performance-Linked Incentives (PLI) for three executive directors, based on the recommendation of the Nomination and Remuneration Committee. The Board cited their pivotal role in business growth and brand development as justification for the payouts.

Additionally, shareholders will ratify the remuneration of M/s Arvind Kumar & Co., Cost Accountants (Firm Registration No. 000646), for the financial year 2026-27. The approved fee is ₹60,000 excluding taxes. The firm’s partner, Mr. Arvind Kumar (Membership No. 37904), has no relationship with the company’s directors or key managerial personnel.

Voting and Compliance Details

The remote e-voting facility will be active from Monday, August 24, 2026, at 9:00 am IST, until Wednesday, August 26, 2026, at 5:00 pm IST. Only members recorded in the Register of Members or Register of Beneficial Owners as of the cut-off date, August 20, 2026, are eligible to vote. Mr. Deep Shukla of Deep Shukla & Associates, Company Secretaries, has been appointed as the Scrutinizer to oversee the voting process and declare results within 48 hours of the meeting's conclusion.

Shareholders attending via video conferencing must register through the InstaMeet platform. Those who have already cast remote e-votes may attend but cannot vote again during the live session. The company emphasizes that all transfers of physical securities must be in demat mode, as per SEBI circulars effective from January 25, 2022.

Kilitch Drugs has commenced nutraceutical manufacturing at its new plant located in Village Maldev, Taluka Pen, District Raigad, Maharashtra on June 17, 2026. This operational expansion marks a significant milestone in the company's strategy to scale its presence in the nutraceutical segment.

Facility Details

The new manufacturing block is situated in the Raigad district of Maharashtra. The following table outlines the key parameters of the development:

Strategic Expansion

The commissioning of the Maldev facility represents a direct expansion of Kilitch Drugs' manufacturing capabilities. By establishing this new production block, the company aims to leverage the growing demand for nutraceutical products in India. This move underscores the company's commitment to enhancing its footprint in this specific category.